[go: up one dir, main page]

WO2002026960A3 - Modulation of gene expression using localization domains - Google Patents

Modulation of gene expression using localization domains Download PDF

Info

Publication number
WO2002026960A3
WO2002026960A3 PCT/US2001/042377 US0142377W WO0226960A3 WO 2002026960 A3 WO2002026960 A3 WO 2002026960A3 US 0142377 W US0142377 W US 0142377W WO 0226960 A3 WO0226960 A3 WO 0226960A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
modulation
domains
localization domains
localization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/042377
Other languages
French (fr)
Other versions
WO2002026960A2 (en
Inventor
Alan P Di Wolffe
Fyodor Urnov
Albert Lai
Eva Raschke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangamo Therapeutics Inc
Original Assignee
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Biosciences Inc filed Critical Sangamo Biosciences Inc
Priority to AU2002213431A priority Critical patent/AU2002213431A1/en
Publication of WO2002026960A2 publication Critical patent/WO2002026960A2/en
Anticipated expiration legal-status Critical
Publication of WO2002026960A3 publication Critical patent/WO2002026960A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/822—Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Insects & Arthropods (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Methods and compositions for regulating gene expression are provided. In particular, methods and compositions comprising localization domains, and fusions of localization domains with DNA binding domains and, optionally regulatory domains, are provided.
PCT/US2001/042377 2000-09-29 2001-09-28 Modulation of gene expression using localization domains Ceased WO2002026960A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002213431A AU2002213431A1 (en) 2000-09-29 2001-09-28 Modulation of gene expression using localization domains

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23688400P 2000-09-29 2000-09-29
US60/236,884 2000-09-29

Publications (2)

Publication Number Publication Date
WO2002026960A2 WO2002026960A2 (en) 2002-04-04
WO2002026960A3 true WO2002026960A3 (en) 2003-04-17

Family

ID=22891390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/042377 Ceased WO2002026960A2 (en) 2000-09-29 2001-09-28 Modulation of gene expression using localization domains

Country Status (2)

Country Link
AU (1) AU2002213431A1 (en)
WO (1) WO2002026960A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
JP2006509010A (en) * 2002-12-05 2006-03-16 インペリアル・カレッジ・イノベイションズ・リミテッド Control of apoptosis
AU2004274957B2 (en) 2003-09-19 2009-02-05 Sangamo Therapeutics, Inc. Engineered zinc finger proteins for regulation of gene expression
AU2007334468B2 (en) 2006-12-14 2013-02-07 Corteva Agriscience Llc Optimized non-canonical zinc finger proteins
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011972A1 (en) * 1995-09-28 1997-04-03 The Trustees Of Columbia University In The City Of New York Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
WO2000041566A1 (en) * 1999-01-12 2000-07-20 Sanagamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2000042219A1 (en) * 1999-01-12 2000-07-20 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
WO2001030843A1 (en) * 1999-10-25 2001-05-03 Novartis Ag Ligand activated transcriptional regulator proteins
WO2001083793A2 (en) * 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Targeted modification of chromatin structure

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011972A1 (en) * 1995-09-28 1997-04-03 The Trustees Of Columbia University In The City Of New York Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
WO2000041566A1 (en) * 1999-01-12 2000-07-20 Sanagamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2000042219A1 (en) * 1999-01-12 2000-07-20 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
WO2001030843A1 (en) * 1999-10-25 2001-05-03 Novartis Ag Ligand activated transcriptional regulator proteins
WO2001083793A2 (en) * 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Targeted modification of chromatin structure

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOEKE JOERN ET AL: "The minimal repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds directly to Sin3A.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 45, 18 August 2000 (2000-08-18), pages 34963 - 34967, XP002215833, ISSN: 0021-9258 *
CROSS S H ET AL: "PURIFICATION OF CPG ISLANDS USING A METHYLATED DNA BINDING COLUMN", NATURE GENETICS, NEW YORK, NY, US, vol. 6, no. 3, 1 March 1994 (1994-03-01), pages 236 - 244, XP000578157, ISSN: 1061-4036 *
KALUDOV NIKOLA K ET AL: "MeCP2 driven transcriptional repression in vitro: Selectivity for methylated DNA, action at a distance and contacts with the basal transcription machinery.", NUCLEIC ACIDS RESEARCH, vol. 28, no. 9, 1 May 2000 (2000-05-01), pages 1921 - 1928, XP002215832, ISSN: 0305-1048 *
NAN XINSHENG ET AL: "MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin.", CELL, vol. 88, no. 4, 1997, pages 471 - 481, XP002215831, ISSN: 0092-8674 *
STEENSEL VAN B ET AL: "Identification of in vivo DNA targets of chromatin proteins using tethered Dam methyltransferase", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 18, no. 4, April 2000 (2000-04-01), pages 424 - 428, XP002187507, ISSN: 1087-0156 *
WOLFFE A P ET AL: "CO-REPRESSOR COMPLEXES AND REMODELLING CHROMATIN FOR REPRESSION", BIOCHEMICAL SOCIETY TRANSACTIONS, COLCHESTER, ESSEX, GB, vol. 28, no. 4, August 2000 (2000-08-01), pages 379 - 386, XP001052910, ISSN: 0300-5127 *

Also Published As

Publication number Publication date
AU2002213431A1 (en) 2002-04-08
WO2002026960A2 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
WO2005044976A3 (en) Oligomeric compounds for use in gene modulation
AU6322900A (en) Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2002044376A8 (en) Modulation of gene expression using insulator binding proteins
WO2001075087A8 (en) Subtilisin variants
WO2002016583A3 (en) Constructs and their use in metabolic pathway engineering
AU9125198A (en) Compositions, kits, and methods for effecting adenine nucleotide modulation of dna mismatch recognition proteins
WO2003012057A3 (en) Antisense modulation of serum amyloid a4 expression
WO2001002019A3 (en) Control of gene expression
WO2003010284A3 (en) Antisense modulation of c-reactive protein expression
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2002026960A3 (en) Modulation of gene expression using localization domains
WO2004024940A3 (en) Rna-mediated gene modulation
AU2003234198A1 (en) Novel genes, compositions, and methods for modulating the unfolded protein response
AU2001238212A1 (en) Modified fluorescent proteins
AU2001264935A1 (en) Method for introducing and expressing genes in animal cells, and bacterial blebsfor use in same
AU2002228805A1 (en) Antisense modulation of damage-specific dna binding protein 2, p48 expression
WO2001029175A3 (en) Antisense modulation of fra-1 expression
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
WO2002062954A3 (en) Antisense modulation of casein kinase 2-beta expression
WO2002050248A3 (en) Antisense modulation of hepsin expression
WO2003030826A3 (en) Antisense modulation of insulin-like growth factor binding protein 5 expression
WO2003012031A3 (en) Antisense modulation of stearoyl-coa desaturase expression
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP